Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR
- PDF / 481,538 Bytes
- 2 Pages / 610 x 792 pts Page_size
- 108 Downloads / 186 Views
BioMed Central
Open Access
Poster presentation
Type of lipid lowering therapy impacts atherosclerosis progression in peripheral arterial disease as assessed by CMR Amy M West*, Justin D Anderson, Craig H Meyer, Fred H Epstein, Klaus D Hagspiel, Stuart S Berr, Nancy L Harthun, Joseph M DiMaria, Jennifer R Hunter, John M Christopher, Gabriel B Winberry, Edward J Van Opstal, Joshua D Chew and Christopher M Kramer Address: University of Virginia, Charlottesville, VA, USA * Corresponding author
from 13th Annual SCMR Scientific Sessions Phoenix, AZ, USA. 21-24 January 2010 Published: 21 January 2010 Journal of Cardiovascular Magnetic Resonance 2010, 12(Suppl 1):P130
doi:10.1186/1532-429X-12-S1-P130
Abstracts of the 13th Annual SCMR Scientific Sessions - 2010
Meeting abstracts - A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/files/pdf/1532-429X-11-S1-infoThis abstract is available from: http://jcmr-online.com/content/12/S1/P130 © 2010 West et al; licensee BioMed Central Ltd.
Introduction
Results
Lipid lowering may improve exercise performance in peripheral arterial disease (PAD), but it is unknown how it affects local vessel wall atherosclerosis as measured by CMR.
R group designation remains blinded until 2-year followup is finished. LDL at baseline in R was 119 ± 43 mg/dl and fell significantly at one year (81 ± 38, p < 0.001) and remained decreased at two years (83 ± 45). The LDL in Z at baseline was 98 ± 27 mg/dl, decreased significantly at one year (74 ± 35, p = 0.005), and was similar at year 2 (76 ± 27). Total cholesterol changes were similar in both groups. The baseline LDL and total cholesterol in R were greater than Z (p = 0.04 and p = 0.05 respectively), however the year 1 and 2 values were similar between groups. See Table 1 for absolute changes in plaque volume and TVV over time. When expressed as % change over 2 years
Purpose We hypothesized that lowering LDL cholesterol in PAD would reduce superficial femoral artery (SFA) plaque burden assessed by magnetic resonance imaging.
Methods Thirty eight patients with mild-to-moderate symptomatic PAD (mean age 64 ± 10 years, ankle brachial index 0.70 ± 0.13) were followed for two years on lipid lowering therapy. Statin-naïve patients were randomized to simvastatin 40 mg or simvastatin 40 mg plus ezetimibe 10 mg (R group, n = 20). Those already on a statin were given openlabel ezetimibe 10 mg (Z group, n = 18). Patients had the first 15-20 cm of the SFA in their most symptomatic leg imaged with black blood multi-slice turbo spin echo CMR annually (Figure 1). Plaque volume (PV) defined as total vessel volume (TVV) minus lumen volume was measured. Changes in parameters within the R and Z groups over the two years were analyzed with one way ANOVA and between group changes were compared with an unpaired t-test.
Figureat1 year 2image of SFA (arrow) of R patient with less Representative plaque Representative image of SFA (arrow) of R patient with less plaque at year 2.
Page 1 of 2 (p
Data Loading...
